Actos gains market share at Avandia's expense

Share this article:

Sales of Takeda's diabetes drug Actos rose 13% in the two weeks after the Cleveland Clinic issued a report suggesting competitor GlaxoSmithKline's Avandia raised the risk of heart attacks by 43 %.


The number of prescriptions for Avandia fell to 151,807 in the week ending June 1, according to Wolters Kluwer Health cited by Bloomberg News. By contrast, Actos prescriptions rose to 265,723 the last week of May.

The FDA has asked both GSK and Takeda to strengthen warnings on their drugs' labeling about the risk of heart failure.

Since then, shares of Takeda have fallen 4.6% on the Tokyo Stock Exchange, while Glaxo shares recouped some of their loss, rising 2.2 % in London.

Avandia, designed to treat Type 2 diabetes is GSK’s second-best selling drug with $3.3 billion in global sales last year. Actos, with global sales of $2.8 billion, accounted for a quarter of Takeda's revenue last year and was the company's best seller.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.